Genprex

News

Genprex Added to Russell 3000® Index

Genprex was added to the Russell 3000® Index after the market closed on Friday, June 26, 2020 as part of the 2020 Russell U.S. Indexes reconstitution.

Read More

Genprex Receives USAN Approval of Non-Proprietary Name for Lead Drug Candidate

Company executes on corporate communication strategy and advances drug branding initiatives

Read More

Genprex CEO to Interview Live on “The Big Biz Show”

Rodney Varner will be participating in a live interview with the “Big Biz Show,” an emmy-award winning nationally syndicated TV and radio show, on Thursday, June 25.

Read More

Genprex Expands Manufacturing Program with Aldevron to Advance Oncoprex™ Clinical Development

Expansion enables full commercial scale plasmid DNA manufacturing capabilities

Read More

Genprex Scheduled to Join Russell 3000® Index

Genprex is scheduled to join the U.S. broad-market Russell 3000 Index when FTSE Russell, a leading global index provider, reconstitutes its 2020 indices after the markets close on Friday, June 26.

Read More

Genprex to Present at the MoneyShow June Virtual Event

Mr. Varner will deliver an overview of the Company and provide updates on its product pipeline.

Read More

Genprex Honors June as Cancer Immunotherapy Month

Genprex is supporting The Society for Immunotherapy of Cancer (SITC) and the Cancer Research Institute’s Annual Cancer Immunotherapy Month in June.

Read More

Genprex Announces Receipt of $2.5 Million in Cash from Recent Warrant Exercises

The exercised warrants include all warrants that have been issued to investors in the Company’s public financings to date and represent approximately 70% of the Company’s overall outstanding warrants.

Read More

Genprex strikes deal with MD Anderson Cancer Center, adds to momentum in cancer fight

Austin startup a ripe M&A target for big pharma, one expert says

Read More